孕35-37周联合其他生物标志物应用眼动脉多普勒预测子痫前期
这项前瞻性观察研究纳入2287例孕35+0至36+6周孕妇,其中60例(2.6%)发生子痫前期。在假阳性率10%下,眼动脉收缩期第二与第一峰流速比值(PSV ratio)可提高基于母体因素、MAP、UtA-PI、PlGF和sFlt-1的筛查检出率,尤其对评估后3周内分娩的子痫前期。作者认为眼动脉多普勒可能改善筛查性能,但需进一步研究验证。
要点
- 孕35-37周筛查时,眼动脉PSV ratio可提高子痫前期筛查检出率,对3周内分娩者提升更明显。
- 联合母体因素与MAP时,PSV ratio使3周内分娩子痫前期检出率从74.1%升至83.4%(FPR 10%)。
- 联合母体因素、MAP和PlGF时,PSV ratio使任何阶段分娩子痫前期检出率从68.3%升至70.8%(FPR 10%)。
核心结论
- 眼动脉多普勒可能改善孕35-37周子痫前期筛查性能,尤其对评估后3周内分娩的临近子痫前期,但需进一步研究验证。
研究设计与样本
- 前瞻性观察研究,纳入2287例孕35+0至36+6周在医院常规产检的孕妇。
- 检查包括母体人口学特征与病史、胎儿解剖与生长超声、母体眼动脉血流速度波形、MAP、UtA-PI、血清PlGF和sFlt-1。
- 采用竞争风险模型估算个体化子痫前期分娩风险,以ROC曲线下面积和假阳性率10%下的检出率评估筛查性能。
诊断标准与关键数值
- 任何阶段分娩子痫前期检出率(FPR 10%):母体因素25.4% vs 母体因素+PSV ratio 50.6%;母体因素+MAP 54.3% vs 加PSV ratio 62.7%;母体因素+MAP+PlGF 68.3% vs 加PSV ratio 70.8%;母体因素+MAP+PlGF+sFlt-1 75.7% vs 加PSV ratio 76.7%。
- 评估后3周内分娩子痫前期检出率(FPR 10%):母体因素31.0% vs 加PSV ratio 69.4%;母体因素+MAP 74.1% vs 加PSV ratio 83.4%;母体因素+MAP+UtA-PI 77.1% vs 加PSV ratio 85.0%;母体因素+MAP+PlGF 84.8% vs 加PSV ratio 88.6%。
- 母体因素+MAP+PSV ratio筛查任何阶段分娩妊娠期高血压检出率59.4%(95% CI 58.6-82.5%),评估后3周内分娩者86.7%(95% CI 82.4-100%)。
临床应用与阅片要点
- 孕35-37周筛查子痫前期时,可在母体因素、MAP、UtA-PI、PlGF和sFlt-1基础上联合眼动脉PSV ratio,以提高检出率。
- 眼动脉PSV ratio对评估后3周内分娩的子痫前期检出率提升幅度大于任何阶段分娩者。
局限性
- 原文结论指出需进一步研究验证该发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To examine the potential value of maternal ophthalmic artery Doppler at 35-37 weeks' gestation in combination with the established biomarkers of pre-eclampsia (PE), including mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1), in the prediction of subsequent development of PE.
METHODS: This was a prospective observational study in women attending for a routine hospital visit at 35 + 0 to 36 + 6 weeks' gestation. This visit included recording of maternal demographic characteristics and medical history, ultrasound examination for fetal anatomy and growth, assessment of flow velocity waveforms from the maternal ophthalmic arteries, and measurement of MAP, UtA-PI, serum PlGF and serum sFlt-1. The competing-risks model was used to estimate the individual patient-specific risks of delivery with PE at any time and at < 3 weeks after assessment by a combination of maternal demographic characteristics and medical history with biomarkers. The area under the receiver-operating-characteristics curve and detection rate (DR) of delivery with PE, at a 10% false-positive rate (FPR), in screening by combinations of maternal factors with ophthalmic artery second to first peak of systolic velocity ratio (PSV ratio), MAP, UtA-PI, serum PlGF and serum sFlt-1 were determined. The modeled performance of screening for PE was also estimated.
RESULTS: The study population of 2287 pregnancies contained 60 (2.6%) that developed PE, including 19 (0.8%) that delivered with PE at < 3 weeks after assessment. The PSV ratio improved the prediction of PE with delivery at any stage after assessment provided by maternal factors alone (from 25.4% to 50.6%), maternal factors and MAP (54.3% to 62.7%), maternal factors, MAP and PlGF (68.3% to 70.8%) and maternal factors, MAP, PlGF and sFlt-1 (75.7% to 76.7%), at a FPR of 10%. The PSV ratio also improved the prediction of PE with delivery at < 3 weeks after assessment provided by maternal factors alone (from 31.0% to 69.4%), maternal factors and MAP (74.1% to 83.4%), maternal factors, MAP and UtA-PI (77.1% to 85.0%) and maternal factors, MAP and PlGF (84.8% to 88.6%). The empirical results for DR at a 10% FPR were consistent with the modeled results. Screening by a combination of maternal factors with MAP and PSV ratio also detected 59.4% (95% CI, 58.6-82.5%) of cases of gestational hypertension with delivery at any stage after assessment, and 86.7% (95% CI, 82.4-100%) of those with delivery at < 3 weeks after assessment.
CONCLUSION: Ophthalmic artery Doppler could potentially improve the performance of screening for PE at 35-37 weeks, especially imminent PE with delivery within 3 weeks after assessment, but further studies are needed to validate this finding. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Sarno M, Wright A, Vieira N, et al. Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 35-37 weeks' gestation. Ultrasound Obstet Gynecol. 2021. PMID: 33073902. doi:10.1002/uog.23517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。